Prevention of anastomotic thrombosis by botulinum toxin a in an animal model

Plastic and Reconstructive Surgery

Volumn 123, Issue 1, 2009, Pages 64-70

  Clemens, Mark W ^a   Higgins, James P ^a   Wilgis, E F Shaw ^a  

^a UNION MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; PHENYLEPHRINE; SODIUM CHLORIDE; MUSCLE RELAXANT AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DIAMETER; ARTICLE; BLOOD VESSEL DIAMETER; BLOOD VESSEL SHUNT; COLD TREATMENT; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFICACY; DRUG TOLERABILITY; FEMORAL ARTERY; FEMORAL VEIN; FREE TISSUE GRAFT; GRAFT SURVIVAL; NEUROMUSCULAR BLOCKING; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT OUTCOME; VASCULAR PATENCY; VASOSPASM; VEIN DIAMETER; ANASTOMOSIS; ANIMAL; POSTOPERATIVE COMPLICATION; SPRAGUE DAWLEY RAT;

ANASTOMOSIS, SURGICAL; ANIMALS; BOTULINUM TOXIN TYPE A; DISEASE MODELS, ANIMAL; NEUROMUSCULAR AGENTS; POSTOPERATIVE COMPLICATIONS; RATS; RATS, SPRAGUE-DAWLEY; THROMBOSIS;

EID: 60549089566     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/PRS.0b013e3181904c31     Document Type: Article

References (27)

1. Khouri RK. Avoiding free flap failure. Clin Plast Surg. 1992; 19:773-781.
2. Nahabedian MY, Momen B, Manson PN. Factors associated with anastomotic failure after microvascular reconstruction of the breast. Plast Reconstr Surg. 2004;114:74-82.
3. Wilgis EF. Evaluation and treatment of chronic digital ischemia. Ann Surg. 1981;193:693-698.
4. Wilgis EF. Digital sympathectomy for vascular insufficiency. Hand Clin. 1985;1:361-367.
5. Freedman RR. Behavioral treatment of Raynaud's disease and phenomenon. Adv Micricirc. 1985;12:138-156.
6. Sycha T, Graninger M, Auff E, Schnider P. Botulinum toxin in the treatment of Raynaud's phenomenon: A pilot study. Eur J Clin Invest. 2004;34:312-313.
7. Van Beek AL, Lim PK, Gear AJ, Pritzker MR. Management of vasospastic disorders with botulinum toxin A. Plast Reconstr Surg. 2007;119:217-226.
8. Rohrich RJ, Janis JE, Fagien S, Stuzin JM. The cosmetic use of botulinum toxin. Plast Reconstr Surg. 2003;112(Suppl): 177S-188S.
9. Fagien S. Extended use of botulinum toxin A in facial aesthetic surgery. Aesthetic Surg. 1998;18:215-219.
10. Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry. 1990;53:633-639.
11. Laskawi R, Drobik C, Schonebeck C. Up-to-date report of botulinum toxin type A treatment in patients with gustatory sweating (Frey's syndrome). Laryngoscope. 1998;108:381-384.
12. Illowsky K, Hallett M. Botulinum toxin treatment of focal hand dystonia. In Jankovic J, Hallett M, eds. Therapy with Botulinum Toxin. New York: Marcel Dekker; 1994:299-306.
13. Samton J, Mauskop A. Treatment of headaches with botuli-num toxin. Expert Rev Neurother. 2006;6:313-322.
14. Guyuron B, Tucker T, Kriegler J. Botulinum toxin A and migraine surgery. Plast Reconstr Surg. 2003;112:171S-173S.
15. Glaser DA. The use of botulinum toxins to treat hyperhi-drosis and gustatory sweating syndrome. Neurotox Res. 2006; 9:173-177.
16. Gobel H, Heinze A, Heinze-Kuhn K, Austermann K. Botu-linum toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain. 2001;91:195-199.
17. Huang W, Foster JA, Rogachefsky AS. Pharmacology of bot-ulinum toxin. J Am Acad Dermatol. 2000;43:249-259.
18. Ishikawa H, Mitsui Y, Yoshitomi T, et al. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J Ophthalmol. 2000;44:106-109.
19. Tarabal O, Caldero J, Ribera J, et al. Regulation of motoneu-ronal calcitonin gene-related peptide (CGRP) during axonal growth and neuromuscular synaptic plasticity induced by botulinum toxin in rats. Eur J Neurosci. 1996;8:829-836.
20. Pedersen-Bjergaard U, Nielsen LB, Jensen K, Edvinsson L, Jansen I, Olesen J. Calcitonin gene-related peptide, neuro-kinin A and substance P: Effects on nociception and neu-rogenic inflammation in human skin and temporal muscle. Peptides. 1991;12:333-337.
21. Meunier FA, Colasante C, Faille L, Gastard M, Molgo J. Upregulation of calcitonin gene-related peptide at mouse motor nerve terminals poisoned with botulinum type-A toxin. Pflugers Arch. 1996;431:R297-R298.
22. Morris JL, Jobling P, Gibbins IL. Differential inhibition by botulinum neurotoxin A of cotransmitters released from autonomic vasodilator neurons. Am J Physiol. 2001;281: H2124-H2132.
23. Jinsi-Parimoo A, Deth RC. Reconstitution of alpha2D-adren-ergic receptor coupling to phospholipase D in a PC12 cell lysate. J Biol Chem. 1997;272:14556-14561.
24. Matic DB, Lee TY, Wells RG, Gan BS. The effects of botu-linum toxin type A on muscle blood perfusion and metabolism. Plast Reconstr Surg. 2007;120:1823-1833.
25. Fanua SP, Wilgis EFS. An easier and more efficient approach for resecting and exposing the femoral artery in rats. J Invest Surg. 2004;17:345-346.
26. Lange DJ, Brin MF, Warner CL, Fahn S, Lovelace RE. Distant effects of local injection of botulinum toxin. Muscle Nerve. 1987;10:552-555.
27. Battista V, Fanua SP, Shaw Wilgis EF. Does the nicotine patch help in the postoperative period for arterial vessel repair? Microsurgery. 2008;28:179-181.